List of Excipients in Branded Drug EYE ITCH RELIEF

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Walgreen Company	EYE ITCH RELIEF	ketotifen fumarate	0363-0038	BENZALKONIUM CHLORIDE
Walgreen Company	EYE ITCH RELIEF	ketotifen fumarate	0363-0038	GLYCERIN
Walgreen Company	EYE ITCH RELIEF	ketotifen fumarate	0363-0038	HYDROCHLORIC ACID
Walgreen Company	EYE ITCH RELIEF	ketotifen fumarate	0363-0038	SODIUM HYDROXIDE
Walgreen Company	EYE ITCH RELIEF	ketotifen fumarate	0363-0038	WATER
Target Corporation	EYE ITCH RELIEF	ketotifen fumarate	11673-064	BENZALKONIUM CHLORIDE
Target Corporation	EYE ITCH RELIEF	ketotifen fumarate	11673-064	GLYCERIN

Generic Drugs Containing EYE ITCH RELIEF

Company	Ingredient	NDC	Excipient
Walgreens	ketotifen fumarate	0363-0610	BENZALKONIUM CHLORIDE
Walgreens	ketotifen fumarate	0363-0610	GLYCERIN
Walgreens	ketotifen fumarate	0363-0610	HYDROCHLORIC ACID
Walgreens	ketotifen fumarate	0363-0610	SODIUM HYDROXIDE
Walgreens	ketotifen fumarate	0363-0610	WATER
Rugby Laboratories	ketotifen fumarate	0536-1096	BENZALKONIUM CHLORIDE
Rugby Laboratories	ketotifen fumarate	0536-1096	GLYCERIN

What are the Most Frequently-Used Excipients in EYE ITCH RELIEF?

# Of NDCs	Excipient
10	BENZALKONIUM CHLORIDE
10	GLYCERIN
9	HYDROCHLORIC ACID
9	SODIUM HYDROXIDE
10	WATER

Excipient Strategy and Commercial Opportunities for Eye Itch Relief

Last updated: February 26, 2026

What are the key excipient considerations for Eye Itch Relief formulations?

Excipient selection impacts product stability, efficacy, patient tolerability, and manufacturing. For eye itch relief medications—typically anti-allergy eye drops—excipients serve functions such as viscosity enhancement, pH buffering, preservative activity, and isotonicity. Common excipients include:

• Preservatives: Benzalkonium chloride (BAK), although preservative-free options like purified water with alternative agents are increasingly common.
• Viscosity agents: Hydroxypropyl methylcellulose (HPMC), carboxymethylcellulose (CMC), and povidone improve dwell time on the ocular surface.
• Buffering agents: Sodium phosphate, sodium borate maintain physiological pH (around 7.4).
• Tonicity agents: Sodium chloride adjusts osmolality to match natural tears (~300 mOsm/kg).

Choosing excipients involves balancing antimicrobial protection, comfort, and preservative sensitivity considerations. Formulations must adhere to stability standards, avoid retinal or corneal toxicity, and optimize shelf life.

Which regulatory and manufacturing trends shape excipient strategies?

The industry trends favor preservative-free formulations due to increased patient sensitivity and regulatory restrictions. The U.S. FDA permits preservative-free multi-dose bottles if aseptic manufacturing techniques are used; single-dose units eliminate the need for preservatives.

Manufacturers explore alternative excipients, such as:

• Polyquaternium-1: Preservative that stabilizes formulations without BAK.
• Hydrophilic polymers: For enhanced viscosity without viscosity-increasing preservatives.
• Hydroxypropyl guar and similar agents are produced under strict GMP standards for compatibility with ocular tissues.

Excipients must meet pharmacopeia standards (USP, EP) and demonstrate non-irritancy in ocular tissues, especially given the sensitive route of administration.

What are the commercial opportunities for excipient suppliers and formulators?

The eye itch relief segment shows growth driven by rising allergy prevalence and aging populations. Key market drivers include:

• Shift to preservative-free formulations: Nearly 30% of prescription ophthalmic drops are preservative-free, with CAGR of approx. 6% over the past five years (IQVIA, 2022).
• Patient comfort and compliance: Improved excipient profiles enhance tolerability, expanding market size.
• Patent expiries of branded products: Generics and OTC products offer opportunities to introduce formulations with optimized excipients.

Opportunities for excipient suppliers include:

• Developing preservative alternatives meeting regulatory compliance.
• Providing high-purity, ophthalmic-grade polymers and buffers.
• Custom formulations targeting niche markets like preservative-free multi-dose systems.

Formulators can capture market share by innovating with minimized excipient irritation, extending shelf life, and reducing manufacturing costs through optimized excipient combinations.

How do excipient strategies impact product differentiation and market entry?

Product differentiation hinges on:

• Preservative-free formulations: Offer convenience and reduced irritation benefit for sensitive patients.
• Enhanced stability: Using novel buffers or stabilizers prolongs shelf life, reduces waste.
• Ease of use: Single-dose units simplify administration and improve compliance.

Lower formulation costs through the utilization of cost-effective excipients can facilitate competitive pricing. Regulatory acceptance and high-quality excipient supply chains are essential for market entry.

What are the key regulatory and safety considerations?

• Safety assessments focus on ocular irritation, sensitization, and systemic exposure.
• Preservative-free products require validated aseptic manufacturing.
• Formulators must demonstrate compatibility with active ingredients and stability over product shelf life.
• The choice of excipients must align with regulatory standards from agencies such as the FDA, EMA, or WHO.

Summary table: Excipient profiles in Eye Itch Relief formulations

Function	Common Excipients	Regulatory Standards	Key Considerations
Preservative activity	BAK, polyquaternium-1	FDA, USP, EP	Allergic potential, preservative-free options
Viscosity enhancement	HPMC, CMC, povidone	USP, EP	Tear film compatibility, irritation risk
pH buffering	Sodium phosphate, borates	USP, EP	Stability, ocular tissue compatibility
Isotonicity	Sodium chloride	USP, EP	Comfort, compatibility with natural tears

Key Takeaways

• Excipient choice in eye itch relief hinges on balancing efficacy, safety, and patient comfort.
• Preservative-free formulations are increasingly prevalent, driven by regulatory and market demand.
• Market trends favor innovations in viscosity agents, buffers, and preservative systems.
• Suppliers focusing on high-purity, ophthalmic-grade excipients can capitalize on growth opportunities.
• Regulatory compliance and safety evaluations remain critical in excipient selection and product development.

FAQs

1. What are the main challenges in formulating preservative-free eye itch relief drops?

Ensuring sterility without preservatives requires aseptic manufacturing and single-dose delivery systems, which entail higher production costs and logistical considerations.

2. How does excipient selection influence product shelf life?

Excipients stabilize active ingredients and inhibit microbial growth, thereby extending shelf life. Compatibility and stability data guide formulation design.

3. Are there new excipients emerging for ocular applications?

Yes, hydrophilic polymers and bio-friendly buffers are being developed to improve tolerability and reduce irritation.

4. What regulatory hurdles exist for preservative-free formulations?

Manufacturers must validate sterilization processes and aseptic manufacturing, with comprehensive stability and safety testing to meet standards.

5. How can a company differentiate its eye itch relief product?

By offering preservative-free, high-viscosity formulations with enhanced patient comfort and minimal irritation, supported by regulatory compliance and manufacturing efficiency.

---

References

[1] IQVIA. (2022). Ophthalmic market analysis 2022.
[2] U.S. Pharmacopeia. (2021). General chapters on ophthalmic preparations.
[3] European Medicines Agency.. Guidelines on ophthalmic products.